Project Grant RF1NS142871
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $1.3M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
- The Project Grant award of $451,000.00 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) is funding research at the University of Texas Southwestern Medical Center (UT Southwestern) to identify genes on human chromosome 21 that contribute to the neurological and developmental impairments associated with Down syndrome. The 2-year project will use CRISPR interference (CRISPRi) technology and induced pluripotent stem cells (iPSCs) derived from individuals...
- The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
- This $5.2 million project grant from the Department of Health and Human Services National Institutes of Health Office of the Director, under the Trans-NIH Research Support program, will fund research at the University of Colorado Denver to study neurovascular dysfunction in individuals with Down syndrome revealed by traumatic brain injury. Over three years, the collaborative multi-principal investigator team will establish how trisomy 21-related cellular defects and candidate genes exacerbate...
- This Project Grant award, funded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), is focused on investigating the susceptibility of basal forebrain cholinergic neurons in individuals with Down syndrome. The key objectives of this $111,783 award, which runs from November 9, 2024 to June 30, 2026, are to: 1) determine if there are fewer basal forebrain cholinergic neurons and earlier accumulation of Alzheimer's disease pathology in the early...
- This federal Project Grant award for $152,816.00, provided by the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research), aims to investigate the link between Down's syndrome (trisomy 21) and placentation defects. The research will focus on: Identifying transcriptional differences in implantation-stage trophoblasts between trisomy 21 and euploid induced pluripotent stem cell lines through RNA-sequencing. Assessing the...
- This $462,454 Project Grant award, provided by the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), aims to characterize DNA methylation dynamics in trisomy 21-associated hematopoiesis and leukemia. The project, awarded to the Icahn School of Medicine at Mount Sinai, will employ the institution's innovative single-cell multi-omic sequencing technology, SHARE-ME-SEQ, to map DNA methylation, chromatin...
- The Department of Health and Human Services National Institutes of Health (NIH) awarded a $1,488,578 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the University of Wisconsin-Madison to develop humanized mouse models for studying Down syndrome (DS) immune responses. The project aims to: 1) Create DS hypoimmune gene-edited induced pluripotent stem cell lines and differentiate them into cardiovascular cell therapies, assessing in vitro DS immune responses; and 2)...
- This Project Grant award of $1,303,054 from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) supports research to create new mouse models of Down Syndrome (DS) that better represent the genetic variability seen in humans. The objectives are to identify modifier genes and molecular pathways affecting the variability in skeletal and neurobehavioral traits associated with DS, and determine if improving skeletal defects can ameliorate brain-related...
- This Project Grant award of $241,380 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to advance the understanding of neurodevelopmental disorders (NDDs) and develop innovative therapies. The research program, led by researchers at Boston Children's Hospital, will use single-cell epigenomic technologies to link pathogenic variants in chromatin regulators, such as...